Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (401-410 of 539) with videos related to

Pageof 54
Sort By:
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
Leukemia|February 7, 2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)C Ola Landgren, Ajai Chari, Yael C Cohen, et al.
Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
European Journal of Haematology|March 4, 2011
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaMichel Delforge, Evangelos Terpos, Paul G Richardson, et al.
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Hemasphere|November 21, 2024
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trialElias K Mai, Axel Nogai, Henk M Lokhorst, et al.
Pageof 54

Showing results (401-410 of 539) with videos related to

Sort By:
Pageof 54
Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
Leukemia|February 7, 2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)C Ola Landgren, Ajai Chari, Yael C Cohen, et al.
Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
European Journal of Haematology|March 4, 2011
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaMichel Delforge, Evangelos Terpos, Paul G Richardson, et al.
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Hemasphere|November 21, 2024
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trialElias K Mai, Axel Nogai, Henk M Lokhorst, et al.
Pageof 54